Tech Company Financing Transactions
DiscGenics Funding Round
On 9/27/2017, DiscGenics secured $14 million in Series B financing from private investors and Mitsubishi Corporation.
Transaction Overview
Company Name
Announced On
9/27/2017
Transaction Type
Venture Equity
Amount
$14,000,000
Round
Series B
Investors
private investors (Najeeb Thomas)
Mitsubishi Corporation (Junichi Masuda)
Proceeds Purpose
Our investment in DiscGenics enables us to play an important role in the development of a potentially game-changing technology while continuing to build our biotechnology investment portfolio.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5940 W Harold Gatty Dr. 106
Salt Lake City, UT 84116
USA
Salt Lake City, UT 84116
USA
Phone
Website
Email Address
Overview
We are a biotechnology company developing advanced spinal stem cell therapeutics to treat patients with diseases of the intervertebral disc.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Flagg Flanagan
Chief Medical Officer
Kevin Foley
Chief Operating Officer
Bob Wynalek
Browse more venture capital transactions:
Prev: 9/27/2017: Ritual venture capital transaction
Next: 9/27/2017: Deep Genomics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs